43
12
5
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T6053 | Turofexorate Isopropyl | XL335,FXR-450,WAY-362450 | FXR , Autophagy |
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM | |||
T40302 | FXR/TGR5 agonist 1 | ||
FXR/TGR5 agonist 1 acts as an agonist on both FXR and TGR5 receptors and is utilized for treating fatty liver disease. | |||
T64144 | FXR antagonist 1 | ||
FXR antagonist 1 is a selective, orally active intestinal FXR antagonist with an IC50 value of 2.1 μM. FXR antagonist 1 antagonises intestinal FXR and selectively inhibits intestinal FXR signalling by feedback activation... | |||
T74996 | FXR agonist 3 | ||
FXR agonist 3, an anti-NASH (Non-Alcoholic Steatohepatitis) agent, functions by activating FXR. It demonstrates anti-fibrogenic activity by inhibiting the expression of COL1A1, TGF-β1, α-SMA, and TIMP1. Additionally, it ... | |||
T72889 | FXR agonist 4 | ||
FXR agonist 4 with an EC 50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of ... | |||
T75160 | FXR agonist 5 | ||
FXR agonist 5 (compound 1), an FXR agonist, is utilized in research targeting diseases or disorders associated with metabolic inflammation [1]. | |||
T74754 | FXR antagonist 2 | ||
Compound A-26, also known as FXR antagonist 2, is a diarylamide derivative that functions as a moderate FXR antagonist. It is utilized in researching hyperlipidemia and type 2 diabetes [1]. | |||
T2015 | Fexaramine | FXR , Autophagy | |
Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity compared to natural compounds. | |||
T7886 | Nidufexor | FXR , Autophagy | |
Nidufexor is an agonist for the farnesoid X receptor (FXR). | |||
T2233 | GW 4064 | FXR , Autophagy | |
GW 4064 is an effective farnesoid X receptor (FXR) agonist (EC50 =65 nM). | |||
T15806 | LY2562175 | FXR , Autophagy | |
LY2562175 is an effective and selective FXR agonist (EC50: 193 nM). | |||
T6344 | Sevelamer hydrochloride | Sevelamer HCl | FXR , Autophagy |
Sevelamer hydrochloride (Sevelamer HCl) is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption. | |||
T31587 | DY268 | DY 268,DY-268 | FXR |
DY268 is a compound based on trisubstituted pyrazolamide without any FXR agonist activity and cytotoxicity and can be used as an effective FXR antagonist (IC50 = 7.5 nM). | |||
T4379 | Tropifexor | LJN452 | FXR , Autophagy |
Tropifexor (LJN452) is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM. | |||
T7436 | Cilofexor | FXR , Autophagy | |
Cilofexor inhibits binding of a synthetic peptide, Cilofexor is a farnesoid X receptor (FXR) agonist. | |||
T11428 | Glyco-Obeticholic acid | FXR | |
Glyco-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an agonist of the farnesoid X receptor (FXR). | |||
T2601 | Vidofludimus | SC12267,4sc-101 | Dehydrogenase , DNA/RNA Synthesis , Interleukin |
Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). | |||
T8471 | Vonafexor | EYP001,PLX007,pxl007 | FXR , HBV |
Vonafexor (EYP001) is a farnesoid X receptor (FXR, NR1H4) agonist, with anti-HBV effects | |||
TQ0252 | BAR502 | FXR , GPCR19 , Autophagy | |
BAR502 is a dual GPBAR1 and FXR agonist (IC50s: 0.4 μM and 2 μM). | |||
T1789 | Obeticholic Acid | INT-747,6-Ethylchenodeoxycholic acid,6-ECDCA | FXR , Autophagy |
Obeticholic Acid (6-ECDCA) is a Farnesoid X Receptor Agonist. The mechanism of action of obeticholic acid is as a Farnesoid X Receptor Agonist. | |||
T6690 | T0901317 | Apoptosis , FXR , Liver X Receptor , ROR | |
T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively; it inhibits nuclear factor/κB (NF/κB). | |||
T27460 | GSK2324 | GSK-2324,GSK 2324 | FXR |
GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis. | |||
T63042 | NDB | FXR | |
NDB is a selective and potent hFXRα antagonist that inhibits GW4064-stimulated FXR/RXR interactions and FXRα target gene expression in primary mouse hepatocytes.NDB is used in the study of diabetes. | |||
T11426 | Gly-β-MCA | FXR | |
Gly-β-MCA is an orally bioactive, enteroselective and potent inhibitor of the farnesoid X receptor (FXR), a bile acid, used in the study of obesity and diabetes. | |||
T8818 | TC-G 1005 | GPCR19 | |
TC-G 1005 is a potent and selective GPBA agonist (EC50 :0.72 nM; hTGR5). Selective for TGR5 over FXR (farnesoid X receptor). Increases plasma GLP-1 levels and reduces blood glucose in mice. Orally available. | |||
T12583 | PX20606 trans racemate | PX-102 trans racemate | Others |
PX20606 trans racemate is an agonist of FXR (EC50s of 32 and 34 nM for FXR in FRET and M1H assay, respectively). | |||
T13093 | Tauro-β-muricholic acid sodium | T-βMCA sodium | FXR |
Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM). | |||
T68612 | DM175 | ||
DM175 is a novel partial FXR agonist, causing specific modulatory effects on FXR activity that clearly differ from classical FXR agonists. | |||
T25417 | Fexarene | ||
Fexarene is a non-steroidal FXR agonist. | |||
T24837 | ST-1892 | ||
ST-1892 is a soluble partial FXR agonist. | |||
T27492 | GSK-8062 | GSK 8062 | |
GSK-8062 is an agonist of farnesoid X receptor (FXR). | |||
T73414 | EDP-305 | ||
EDP-305, an orally active, potent, and selective agonist of the farnesoid X receptor (FXR), exhibits EC50 values of 34 nM in chimeric FXR within CHO cells and 8 nM in full-length FXR in HEK cells. Demonstrating a potent ... | |||
T12251 | NR1H4 activator 1 | Others | |
NR1H4 activator 1 is a potent and selective agonist of Famesoid X Receptor (FXR). | |||
T63818 | Omesdafexor | ||
Omesdafexor is an FXR agonist that can be used to study diseases caused by liver disease or metabolic inflammation. | |||
T70899 | Vidofludimus hemicalcium | 4sc-101 hemicalcium,SC12267 hemicalcium,4sc-101 hemicalcium ; SC12267 hemicalcium | |
Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulat... | |||
T69724 | Cilofexor tromethamine | ||
Cilofexor, also known as GS-9674, is a farnesoid X receptor (FXR) agonist. The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. In clinical study, cilof... | |||
T11661 | INT-767 | FXR , GPCR19 | |
INT-767 is a potent farnesoid X receptor (FXR)/TGR5 dual agonist that prevents NASH and promotes visceral adipose brown lipogenesis and mitochondrial function for the study of non-alcoholic steatohepatitis. | |||
T37414 | CAY10771 | ||
CAY10771 is a dual agonist of farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor δ (PPARδ).1It activates FXR and PPARδ in reporter assays using HEK293T cells (EC50s = 0.94 and 1.5 μM, respectively)... | |||
T69686 | BMS-986318 | ||
BMS-986318 is a potent nonbile acid FXR agonist, displaying EC50 values of 53 nM and 350 nM in FXR Gal4 and SRC-1 recruitment assays, respectively. It exhibits a favorable ADME profile and shows effectiveness in mouse mo... | |||
T78910 | ZLY28 | FXR | |
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1. Additionally, it is a pioneering anti-NASH agent, utilized in the study of n... | |||
T73155 | BMS-986339 | ||
BMS-986339 is an orally active, potent FXR agonist that interacts via H-bond formation with the His298 and ASN287 residues. It is utilized in research focused on primary biliary cirrhosis (PBC), primary sclerosing cholan... | |||
T37416 | Tauro-α-muricholic Acid (sodium salt) | ||
Tauro-α-muricholic acid (TαMCA) is an antagonist of the farnesoid X receptor (FXR; IC50 = 28 μM) and a taurine-conjugated form of the murine-specific primary bile acid α-muricholic acid . TαMCA is common in rodents but h... | |||
T83858 | Tauro-Obeticholic Acid sodium | Tauro-6-Ethylchenodeoxycholic Acid,Tauro-6-Ethyl-CDCA,Obeticholic Acid Taurine Conjugate,Tauro-OCA,T-ECDCA | |
Tauro-obeticholic acid, a farnesoid X receptor (FXR) agonist and semisynthetic derivative of chenodeoxycholic acid, is an active metabolite of obeticholic acid. This compound undergoes taurine conjugation in the liver to... |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T13092 | Tauro-Obeticholic acid | FXR | |
Tauro-Obeticholic acid is an active Obeticholic acid metabolite. Obeticholic acid is an orally bioavailable agonist of farnesoid-X receptor (FXR). | |||
T0847 | Chenodeoxycholic acid | CDCA,Chenodiol | Potassium Channel , FXR , Endogenous Metabolite , Autophagy |
Chenodeoxycholic acid (CDCA) is a bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as ... | |||
T2939 | Forskolin | Coleonol,Colforsin | FXR , Adenylyl cyclase , AChR , Autophagy |
Forskolin (Coleonol) is a natural product, an adenylate cyclase activator (EC50=0.5 μM). Forskolin increases cAMP levels, activates PXR and FXR, and induces autophagy. Forskolin produces positive inotropic effects in the... | |||
T5574 | Guggulsterone | Guggulsterone E&Z | Apoptosis , FXR , Akt , Caspase , JNK , Autophagy |
Guggulsterone (Guggulsterone E&Z) E&Z is a 3-hydroxy steroid. It has a role as an androgen. | |||
T0700 | Ursodeoxycholic acid | UDCA,Ursodiol | Potassium Channel , Endogenous Metabolite |
Ursodeoxycholic acid (UDCA) can be used to dissolve gallstones and reduce cholesterol absorption. | |||
T29078 | Ursodeoxycholic acid sodium | UDCA Na,UDCA sodium,Sodium Ursodeoxycholate,Ursodiol sodium,Ursodeoxycholic Acid (sodium salt),Ursodeoxycholate sodium | FXR , Endogenous Metabolite , GPCR19 |
Ursodeoxycholic acid sodium (Sodium Ursodeoxycholate) is a naturally occurring secondary bile acid with anti-inflammatory and cytoprotective activities. Ursodeoxycholic acid sodium acts as signaling molecule, exerting it... | |||
T6S2246 | Alisol B 23-acetate | Alisol B Acetate,Alisol B monoacetate,23-O-Acetylalisol B,23-Acetylalismol B | Others |
1. Alisol B 23-acetate (Alisol B Acetate) produces protective effect against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes. 2. Alisol B 23-acetate produces promotiv... | |||
T8895 | Altenusin | FXR | |
Altenusin is a natural nonsteroidal fungal metabolite, as a novel selective agonist of FXR with an EC50 value of 3.2 ± 0.2 μM. | |||
T36563 | (E)-Guggulsterone | ||
Bile acids are essential for solubilization and transport of dietary lipids, are the major products of cholesterol catabolism, and are physiological ligands for farnesoid X receptor (FXR), a nuclear receptor that regulat... | |||
T75538 | Alismanol M | ||
Alismanol M, a protostane-type triterpenoid isolated from the rhizome of Alisma orientale, functions as a farnesoid X receptor (FXR) agonist with an EC50 value of 50.25 μM. It is utilized in researching cholestasis and n... | |||
T81030 | Tauro-β-muricholic acid | TβMCA | FXR |
Tauro-β-muricholic acid (TβMCA), a trihydroxylated bile acid, acts as a competitive and reversible FXR antagonist (IC 50 = 40 μM) and exhibits antiapoptotic effects by inhibiting bile acid-induced hepatocellular apoptosi... | |||
TN4628 | Nelumol A | FXR | |
Nelumol A, and nelumal A show a potency comparable to the endogenous ligand, they may as a valuable potential novel lead compound in the search for FXR agonists. |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-06756 | NR1H4 Protein, Mouse, Recombinant (His) | Mouse | E. coli |
TMPY-06768 | NR1H4 Protein, Human, Recombinant (His) | Human | E. coli |
TMPH-01355 | FXR1 Protein, Human, Recombinant (His) | Human | E. coli |
RNA-binding protein required for embryonic and postnatal development of muscle tissue. May regulate intracellular transport and local translation of certain mRNAs. | |||
TMPY-02987 | Vitamin D Receptor/VDR Protein, Mouse, Recombinant (His) | Mouse | Baculovirus-Insect Cells |
VDR (vitamin D (1,25- dihydroxyvitamin D3) receptor), also known as NR1I1, belongs to the NR1I family, NR1 subfamily. It is composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal... | |||
TMPY-02706 | Vitamin D Receptor/VDR Protein, Human, Recombinant (His) | Human | Baculovirus-Insect Cells |
VDR (vitamin D (1,25- dihydroxyvitamin D3) receptor), also known as NR1I1, belongs to the NR1I family, NR1 subfamily. It is composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal... |